CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed early operable adenocarcinoma of the breast
• •No evidence of invasive lobular breast disease
• •Measurable disease, defined as at least 1 lesion ≥ 2 cm by MRI
• •Measurable levels of total choline according to institutional criteria by magnetic resonance spectroscopy
• •Must have available or scheduled core breast biopsy procedure
• •Hormone receptor status not specified
• •PATIENT CHARACTERISTICS:
• •Menopausal status not specified
• •ECOG performance status 0-1
• •Platelet count ≥ 100,000/mm\^³
• •Neutrophil count ≥ 1,500/mm³
• •Creatinine \< 1.5 times upper limit of normal (ULN)
• •Bilirubin \< 1.5 times ULN
• •ALT and AST \< 2.5 times ULN
• •Fertile patients must use adequate barrier method contraception during and for at least 150 days after completion of study treatment
• •Ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
• •No known hypersensitivity to monoclonal antibodies
• •No prior or active malignancies other than curatively treated in situ carcinoma of the cervix, uterus, or basal cell or squamous cell carcinoma of the skin
• •No serious uncontrolled medical disorder or active infection that would impair the ability to receive study treatment
• •No significant active cardiac disease including any of the following:
• •* Uncontrolled high blood pressure (i.e., systolic blood pressure \[BP\] \> 160 mm Hg and diastolic BP \> 95 mm Hg)
• •* Unstable angina
• •* Deep venous thrombosis
• •* Pulmonary embolism
• •* Cerebrovascular attack
• •* Valvular disease
• •* Congestive heart failure
• •* Myocardial infarction with the past 6 months
• •* Serious cardiac arrhythmias
• •No dementia or significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with study requirements
• •PRIOR CONCURRENT THERAPY:
• •More than 4 weeks since prior surgery and recovered
• •More than 2 weeks since high-dose corticosteroid therapy (i.e., ≥ 100 mg prednisone per day or \> 40 mg dexamethasone per day)
• •No prior anti-IGF-1R based investigational therapy
• •No prior systemic therapy for primary disease
• •No concurrent chronic systemic high-dose immunosuppressive steroid therapy
• •* Low-dose steroids for nausea and vomiting control allowed
• •* Topical corticosteroid applications, inhaled sprays, eye drops or local injections (e.g., intraocular) allowed
• •No concurrent other anticancer drugs or therapy